Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

HYCOVID, 2020
 
NCT04325893
RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
124/123 inconclusive
  • inconclusive 12 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
ORCHID, 2020
 
NCT04332991
RCThydroxychloroquineplaceboCOVID 19 hospitalizedlow
242/237 inconclusive
  • inconclusive 2 % increase in clinical improvement (PE) with a high degree of certainty due to low risk of bias
TEACH, 2020
 
NCT04369742
RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
67/61 inconclusive
  • inconclusive 80 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
  • inconclusive 16 % increase in adverse events (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 severe or critically meta-analysis

HYDRA, 2020
 
NCT04315896
RCThydroxychloroquineplaceboCOVID-19 severe or criticallyNA
75/77 inconclusive
  • inconclusive 1 % decrease in deaths (PE)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).